Newron Shares Fall 12% in Zurich Trading as Santhera Talks End

Feb. 3 (Bloomberg) -- Newron Pharmaceuticals SpA, the Italian drugmaker developing a Parkinson’s disease treatment with Merck KGaA, fell in Zurich trading after saying talks with Santhera Pharmaceuticals Holding AG have ended.

The stock fell 80 centimes, or 12 percent, to 5.90 Swiss francs at 9:05 a.m.

Link to Company News:{NWRN SW <Equity> CN <GO>} Link to Company News:{SANN SW <Equity> CN <GO>}

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net